EUVIMEDEUVIMED entdecken
Multizentrische Studie

In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain

Ainhize Maruri-Aransolo, Carla López-Causapé, Marta Hernández-García iD, María García-Castillo, Juan de Dios Caballero-Pérez, Antonio Oliver, Rafael Cantón iD

Journal of Antimicrobial Chemotherapy · 03.06.2024 · 79 (6) · 1432-1440

DOI: 10.1093/jac/dkae126 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 06.05.2024. Verfasst von Ainhize Maruri-Aransolo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas aeruginosa, Cefiderocol, Pseudomonas Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Despite the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Pseudomonas aeruginosa is still a major pathogen in people with cystic fibrosis (pwCF). We determine the activity of cefiderocol and comparators in a collection of 154 P. aeruginosa isolates recovered from pwCF during three multicentre studies performed in 17 Spanish hospitals in 2013, 2017 and 2021.

Methods

ISO broth microdilution was performed and MICs were interpreted with CLSI and EUCAST criteria. Mutation frequency and WGS were also performed.

Results

Overall, 21.4% were MDR, 20.8% XDR and 1.3% pandrug-resistant (PDR). Up to 17% of the isolates showed a hypermutator phenotype. Cefiderocol demonstrated excellent activity; only 13 isolates (8.4%) were cefiderocol resistant by EUCAST (none using CLSI). A high proportion of the isolates resistant to ceftolozane/tazobactam (71.4%), meropenem/vaborbactam (70.0%), imipenem/relebactam (68.0%) and ceftazidime/avibactam (55.6%) were susceptible to cefiderocol. Nine out of 13 cefiderocol-resistant isolates were hypermutators (P < 0.001). Eighty-three STs were detected, with ST98 being the most frequent. Only one isolate belonging to the ST175 high-risk clone carried blaVIM-2. Exclusive mutations affecting genes involved in membrane permeability, AmpC overexpression (L320P-AmpC) and efflux pump up-regulation were found in cefiderocol-resistant isolates (MIC = 4–8 mg/L). Cefiderocol resistance could also be associated with mutations in genes related to iron uptake (tonB-dependent receptors and pyochelin/pyoverdine biosynthesis).

Conclusions

Our results position cefiderocol as a therapeutic option in pwCF infected with P. aeruginosa resistant to most recent β-lactam/β-lactamase inhibitor combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPseudomonas aeruginosaCefiderocolPseudomonas InfectionsMicrobial Sensitivity TestsAnti-Bacterial AgentsCephalosporinsHumansSpainDrug Resistance, Multiple, BacterialAdolescentAdultChildMutationTazobactamFemaleMale

Substanzen

CefiderocolAnti-Bacterial AgentsCephalosporinsceftolozane, tazobactam drug combinationTazobactam

Autor:innen und Institutionen

  • Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Servicio de Microbiología, Hospital Universitario de Son Espases and (IdISBa), Palma de Mallorca, Spain.
  • CIBER de Enfermedades Infecciosas CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Marta Hernández-García, Rafael Cantón

Förderung

  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
  • CIBERINFEC
  • Instituto de Salud Carlos III
  • Shionogi

Zitieren

APA

Maruri-Aransolo, A., López-Causapé, C., Hernández-García, M., García-Castillo, M., Caballero-Pérez, J. D., Oliver, A., & Cantón, R. (2024). In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. Journal of Antimicrobial Chemotherapy, 79(6), 1432-1440. https://doi.org/10.1093/jac/dkae126

Vancouver

Maruri-Aransolo A, López-Causapé C, Hernández-García M, García-Castillo M, Caballero-Pérez JD, Oliver A, et al. In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. Journal of Antimicrobial Chemotherapy. 2024;79(6):1432-1440. doi:10.1093/jac/dkae126

BibTeX
@article{MaruriAransolo2024,
  author = {Maruri-Aransolo, Ainhize and López-Causapé, Carla and Hernández-García, Marta and García-Castillo, María and Caballero-Pérez, Juan de Dios and Oliver, Antonio and Cantón, Rafael},
  title = {In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {6},
  pages = {1432--1440},
  doi = {10.1093/jac/dkae126}
}
Kostenlos starten →